Immunomediated Diseases and Innovative Therapies

Overview

The Immunomediated Diseases and Innovative Therapies is a heterogeneous area composed by both translational and clinical research groups which cover fields such as immunology, respiratory and systemic diseases, pharmacology, clinical biochemistry, rheumatology, advanced therapies or transfusional medicine. Its main strength derives precisely from this heterogeneity and the complementarity of the scientific interests and expertise of the different groups, many of which are currently joining efforts and synergizing in a variety of collaborative research projects.

Publications

229

total

1430

impact factor

6.25

average impact factor

Group Leader: Jaume Alijotas Reig

team

zoom

download

Our team has continued working on autoimmune diseases and autoinflammatory disorders. Autoimmune disorders complicating pregnancy have also been a focus of our group. Studies focusing on the role of disturbances among diverse immune cells, cytokines and autoantibodies and their relationship with inflammatory placental-related disorders are ongoing in pregnant women. Animal models have been included in this research. The relationship between myositis and systemic sclerosis and cancer, as well as different autoantibody profiles with certain clinical subsets in both disorders, has been fully analysed. Recent reported autoimmune diseases in oncologic patients treated with check point inhibitors have also focused our interest. Gene-wide genetic and molecular signatures in patients with systemic vasculitis, Sjögren syndrome and systemic sclerosis to find relationship with clinical subsets have been studied. Finally, we also have described a new risk haplotype for developing autoimmune/granulomatous disorders in patients underwent bioimplants.

In summary, this group covers epidemiological, clinical, and basic research attempting to address bed-related concerns from patients to basic research to obtain translational results that permit us to solve these issues that affect a lot of people.

68

total

403

impact factor

5^.93

average impact factor

SELECTED ARTICLES

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, Belizna C, Ruffatti A, Tincani A, Marozio L, Espinosa G, Cervera R, Ríos-Garcés R, De Carolis S, Latino O, LLurba E, Chighizola CB, Gerosa M, Pengo V, Lundelin K, Rovere-Querini P, Canti V, Mayer-Pickel K, Reshetnyak T, Hoxha A, Tabacco S, Stojanovich L, Gogou V, Varoudis A, Arnau A, Ruiz-Hidalgo D, Trapé J, Sos L, Stoppani C, Martí-Cañamares A, Farran-Codina I; EUROAPS Study Group.
The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.
Autoimmun Rev. 2019 Apr;18(4):406-414.
doi: 10.1016/j.autrev.2018.12.006. Epub 2019 Feb 15.
IF: 7.767
Selva-O’Callaghan A, Ros J, Gil-Vila A, Vila-Pijoan G, Trallero-Araguás E, Pinal-Fernandez I.
Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes.
Neuromuscul Disord. 2019 Nov;29(11):819-825.
doi: 10.1016/j.nmd.2019.09.014. Epub 2019 Sep 26.
IF: 3.115
Calderón-Goercke M, Loricera J, Aldasoro V, Castañeda S, Villa I, Humbría A, Moriano C, Romero-Yuste S, Narváez J, Gómez-Arango C, Pérez-Pampín E, Melero R, Becerra-Fernández E, Revenga M, Álvarez-Rivas N, Galisteo C, Sivera F, Olivé-Marqués A, Álvarez Del Buergo M, Marena-Rojas L, Fernández-López C, Navarro F, Raya E, Galindez-Agirregoikoa E, Arca B, Solans-Laqué R, Conesa A, Hidalgo C, Vázquez C, Román-Ivorra JA, Lluch P, Manrique-Arija S, Vela P, De Miguel E, Torres-Martín C, Nieto JC, Ordas-Calvo C, Salgado-Pérez E, Luna-Gomez C, Toyos-Sáenz de Miera FJ, Fernández-Llanio N, García A, Larena C, Palmou-Fontana N, Calvo-Río V, Prieto-Peña D, González-Vela C, Corrales A, Varela-García M, Aurrecoechea E, Dos Santos R, García-Manzanares Á, Ortego N, Fernández S, Ortiz-Sanjuán F, Corteguera M, Hernández JL, González-Gay MÁ, Blanco R.
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Semin Arthritis Rheum. 2019 Aug;49(1):126-135.
doi: 10.1016/j.semarthrit.2019.01.003
IF: 4.751
Callejas-Moraga EL, Guillén-Del-Castillo A, Marín-Sánchez AM, Roca-Herrera M, Balada E, Tolosa-Vilella C, Fonollosa-Pla V, Simeón-Aznar CP.
Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain.
Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):41-48. Epub 2019 Feb 11.
IF: 3.319
Martínez-Valle F, Riveiro-Barciela M, Salcedo MT, Merino-Casabiel X, Fernández-Codina A, Torres I, Esteban R, Buti M.
Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity.
Ann Hepatol. 2019 Jan-Feb;18(1):215-219.
doi: 10.5604/01.3001.0012.7916.
IF: 2.125

View all publications

Immunomediated Diseases and Innovative Therapies

Overview

Publications

Group Leader: Jaume Alijotas Reig

Research Areas